Matthew Fust Buys Shares of Crinetics Pharmaceuticals
Matthew Fust purchased 9,730 shares of Crinetics Pharmaceuticals on June 18, 2026.
Key Points
- Matthew Fust purchased 9,730 shares of Crinetics Pharmaceuticals on June 18, 2026, with the stock trading near $35.91 on Tuesday.
- Crinetics Pharmaceuticals has a market cap of $3.73 billion and a forward P/E ratio of -8.41, reflecting its unprofitable status.
- Analysts like HC Wainwright & Co. and Citizens have reiterated buy ratings, with price targets as high as $95.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 18, 2026, Matthew Fust purchased 9,730 shares of Crinetics Pharmaceuticals, Inc. (NasdaqGS: CRNX). The transaction wasn't part of a pre-planned trading program. Shares of Crinetics traded near $35.91 on Tuesday.
Insider Buying and Selling at Crinetics Pharmaceuticals, Inc.
In addition to Matthew Fust, several other insiders made purchases on June 18, 2026. Wendell Wierenga, Rogerio Vivaldi Coelho, Camille Bedrosian, and Weston Nichols each bought shares, with transactions ranging from 5,925 to 9,730 shares. None of these purchases were made under a Rule 10b5-1 plan.
Other Institutional Activity in Crinetics Pharmaceuticals
FMR LLC increased its holdings by 1,466,024 shares, bringing its total to 15,759,799 shares valued at about $572.4 million, a 10.3% increase. BlackRock, Inc. added 490,267 shares, ending with 8,478,815 shares worth approximately $307.9 million, a 6.1% increase. Farallon Capital Management LLC grew its stake by 1,405,000 shares to 8,338,098 shares, valued at $302.8 million, marking a 20.3% increase. Wellington Management Group LLP increased its position by 119,315 shares to 8,157,204 shares worth $296.3 million, a 1.5% rise. Driehaus Capital Management LLC added 8,182 shares, ending with 6,395,922 shares valued at $232.3 million, a modest 0.1% increase.
Crinetics Pharmaceuticals, Inc. Stock Down 57.3%
Shares of Crinetics Pharmaceuticals traded around $35.91 on Tuesday. The company, with a market cap of approximately $3.73 billion, is not profitable, resulting in a forward P/E ratio of -8.41. The stock's 52-week range spans from $25.83 to $57.99. It has a 50-day moving average of $37.23 and a 200-day moving average of $41.74. Crinetics boasts a strong current ratio of 18.60 and a quick ratio of 18.25, with a debt-to-equity ratio of 3.74.
$CRNX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 15, 2026, HC Wainwright & Co. reiterated a buy rating on Crinetics Pharmaceuticals with a price target of $81.00. Citizens reiterated its buy rating with a target of $95.00 on June 11. Evercore ISI Group maintained its buy rating with an $88.00 target on May 15. The consensus among 14 analysts is a strong buy, with a mean target price of $83.14.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, focusing on developing treatments for rare endocrine diseases and tumors. Led by CEO Dr. R. Scott Struthers, the company is working on several innovative therapeutics, including Paltusotine for acromegaly and carcinoid syndrome, and Atumelnant for diseases caused by excess ACTH. It employs about 594 people.
Bottom Line
Matthew Fust's recent purchase of Crinetics Pharmaceuticals shares highlights ongoing insider interest. Crinetics, while currently unprofitable, continues to attract attention due to its unique focus on rare endocrine conditions. Institutional investors and analysts alike are closely watching its developments, as reflected in recent buy ratings and revised price targets.
Get Crinetics Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CRNX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.